- Home
- BWFG vs CBIO Comparison
BWFG vs CBIO Comparison
Compare BWFG & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BWFG | CBIO |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 525.2M | 537.5M |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BWFG | CBIO |
|---|---|---|
| Price | $66.16 | $16.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $55.00 | $26.67 |
| AVG Volume (30 Days) | 54.5K | ★ 327.7K |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 261.79 | N/A |
| EPS | ★ 2.95 | N/A |
| Revenue | ★ $2,826,000.00 | $18,500.00 |
| Revenue This Year | $17.64 | N/A |
| Revenue Next Year | $6.21 | $279.20 |
| P/E Ratio | $22.35 | ★ N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $40.45 | $8.72 |
| 52 Week High | $69.59 | $27.41 |
Technical Indicators
Market Signals| Indicator | BWFG | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 41.31 |
| Support Level | $65.64 | $14.46 |
| Resistance Level | $69.22 | $18.53 |
| Average True Range (ATR) | 1.57 | 1.52 |
| MACD | -0.25 | -0.43 |
| Stochastic Oscillator | 50.17 | 10.20 |
Price Performance
Historical ComparisonAbout BWFG Bankwell Financial Group Inc.
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.
About CBIO Crescent Biopharma Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.